Avisa Diagnostics Inc FOGCF

Avisa Diagnostics Inc. is a clinical-stage medical device company. The Company is engaged in the development of the Allora BreathTest (ABT), a drug/device biomarker technology platform. The Allora BreathTest (ABT) is an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load. ABT enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via its own delivery systems. Its ABT portfolio includes Post-Covid-19 Bronchiectasis, Develo, Ventilator-Associated Pneumonia (VAP), Chronic Obstructive Pulmonary Disease (COPD), Community-Acquired, Pneumonia (CAP), Cystic Fibrosis, Tuberculosis, Aspergillus Fungus and Clostridium Difficile (C. diff).

GREY:FOGCF - Post by User

Avisa Diagnostics Inc > I FEEL AVISA HAS A BETTER TECHNOLOGY AND FURTHER AHEAD.

<< Previous

Bullboard Posts

Next >>

Comment by Mcgirton Jan 30, 2021 1:35pm

86 Views

Post# 32428705

RE:I FEEL AVISA HAS A BETTER TECHNOLOGY AND FURTHER AHEAD.

That's exactly what I was thinking/hoping would happen with the Avisa device...be converted to detect Covid 19 with a breath test. There are many similarities here. Good find frewil.

"Originally, the technology was being used to develop tests to detect illnesses such as lung cancer, and how to distinguish between bacterial and viral respiratory diseases quickly."

<< Previous

Bullboard Posts

Next >>

Events and communications company provides activity update